Here, we report the case of a patient with stage IV cSCC with lymph node and lung metastases who was refractory to 4 prior lines of therapy, subsequently found to have an ERBB2 (HER2) mutation, and then was switched to trastuzumab with continued response following a year of treatment. The gene discussed is ERBB2; the disease is skin squamous cell carcinoma.